Alliance for Cancer Gene Therapy announces 2 new cancer grant recipients for 2017 – EurekAlert (press release)
|
Alliance for Cancer Gene Therapy announces 2 new cancer grant recipients for 2017
EurekAlert (press release) Throughout the past 15 years, Alliance for Cancer Gene Therapy (ACGT), the nation’s only nonprofit dedicated exclusively to cell and gene therapies for cancer, has been an initial funder for early cancer cell, gene and immunotherapy research in North … |
Esquire.com |
President* Trump vs. His Environment
Esquire.com I wish there was something funny I could write about what’s going to happen to the Environmental Protection Agency once the Senate approves the absurd nomination of Scott Pruitt to head an agency that he is at the moment suing on behalf of the state of … |
Phys.Org |
Modifying fat content in soybean oil with the molecular scissors Cpf1
Phys.Org CRISPR–Cpf1 is introduced into plant cells without cell walls (protoplasts) as a pre-assembled complex of the protein Cpf1 (red scissors) and the CRISPR-RNA (crRNA, in blue). Cpf1 functions as gene scissors that cuts the plant’s DNA (shown …more. Scientists use CRISPR–Cpf1 technology to modify fat in soybean oildomain-B |
Intellectual Property Watch |
New Gene-Editing Technology Whets Appetites In Health, Food Industry, Fuels Patent Fights
Intellectual Property Watch In January, Monsanto announced it had reached “a new global licensing agreement with the Broad Institute of MIT and Harvard for the use of the novel CRISPR–Cpf1 genome-editing technology in agriculture.” CRISPR–Cpf1, according to the release, “is an … |
Immuno-Oncology News |
Immunotherapy Combo Trial for Advanced Solid Tumors Doses First Patient
Immuno-Oncology News A Phase 1 trial assessing a combination of the immune checkpoint inhibitor Yervoy (ipilimumab) and Transgene’s oncolytic virus Pexa-Vec as a treatment for multiple advanced solid tumors has dosed its first patient at the Léon Bérard Cancer Center in … |
|
Lonza to Manufacture Selecta Gene Therapy Candidate for MMA
Genetic Engineering & Biotechnology News Lonza’s viral-based therapeutics unit Lonza Houston has agreed to manufacture an Anc80-AAV–based gene therapy product for Selecta Bioscience’s proprietary program for the treatment of methylmalonic acidemia (MMA) and may produce other … Lonza and Selecta Biosciences (SELB) Announce Manufacturing Agreement for Anc80-AAV-Based Gene TherapyStreetInsider.com |